Genomic, transcriptomic and proteomic databases indicate that the N-terminal 322 residues encoded by the presumptive LOC100996504 gene, which is adjacent to the ARHGEF18 guanine nucleotide exchange factor gene on chromosome 19, constitute the N-terminal portion of a 1361-residue isoform of ARHGEF18, dubbed LOCGEF-X3. LOCGEF-X3 arises from the use of a leukocyte-specific alternative transcriptional start site and splicing that bypasses the initial noncoding exon of the canonical 1015-residue ARHGEF18 isoform, p114. Eosinophil LOCGEF-X3 was amplified and cloned, recombinant LOCGEF-X3 was expressed, and anti-ARHGEF18 antibody was found to recognize a band in immunoblots of eosinophil lysates that co-migrates with recombinant LOCGEF-X3. PCR of eosinophils revealed minor amounts of transcripts for X4 and X5 isoforms of LOCGEF that arise from differential splicing and differ from the X3 isoform at their extreme N-termini. No p114 transcript or protein band was detected in eosinophils. Immunostaining with anti-ARHGEF18 antibody revealed relocalization of LOCGEF and RHOA from the periphery of round unstimulated eosinophils to the 2 poles of eosinophils polarized by treatment with IL5, CCL11, or IL33 in suspension. Canonical p114 ARHGEF18 has been implicated in maintenance of epithelial cell polarity. We suggest that the "LOC" portion of LOCGEF, which is unlike any other protein domain, has unique functions in control of polarity in activated eosinophils and other leukocytes.
INTRODUCTION
Rho guanine nucleotide exchange factor 18 (ARHGEF18) is a widely-expressed Ras homology guanine nucleotide exchange factor (RhoGEF) known to enhance the activity of RHOA GTPase. 1 ARHGEF18 may also modulate RAC1 GTPase, [2] [3] [4] although this activity is controversial. 1, 5 Two variants of human ARHGEF18 are Abbreviations: ARHGEF18, rho guanine nucleotide exchange factor 18; ChIP-Seq, chromatin immunoprecipitation-sequencing; DAPI, 4 ′ ,6-diamidino-2-phenylindole; dbSNP, database of single nucleotide polymorphisms; GEF, guanine nucleotide exchange factor; IPTG, isopropyl -D-1-thiogalactopyranoside; JAK, janus kinase; MGI, mouse Genome Informatics; MLC, myosin light chain; PSI, percentage spliced in; PSM, peptide-sequence match; PVDF, polyvinylidene fluoride; STAT, signal transducer and activator of transcription; ME, -mercaptoethanol annotated in UniProtKB, isoforms 1 and 2. The 114 kDa isoform 2 (hereafter called the p114 isoform) has been characterized and comprises a 1015-residue protein with guanine nucleotide exchange activity and the Dbl and pleckstrin homology domains characteristic of GEFs. 1 In medaka fish, mutation of ARHGEF18 results in dysregulation of RHOA-ROCK2 signaling that maintains neuro-epithelial apico-basal polarity and proliferation. 4 The effects of ARHGEF18 depletion by RNA interference have been characterized in breast cancer cells, 6 endothelial cells, 7 and various types of epithelial cells. 6, 8 ARHGEF18 is necessary for cell-cell junction maturation in endothelial and epithelial cells, [7] [8] [9] intercellular communication of bronchial epithelial cells, 10 and amoeboid movement of breast cancer cells and epithelial sheet closure after corneal wounding. 6, 11 Transfection of ARHGEF18 (p114) in fibroblasts led to increased production of reactive oxygen species 2 and increased RHOA activation. 5 Exogenous expression of the p114 isoform also demonstrated its role in organizing actomyosin cytoskeletal components, thereby regulating stress fiber formation 1, 5 and maintaining neuro-epithelial apico-basal polarity. 4 Arno et al. 12 recently reported 5 mutations in ARHGEF18 that are associated with retinal dystrophy in humans.
The changes phenocopy effects of ARHGEF18 mutations in medaka fish, 4 and thus the association has been attributed to the contribution of ARHGEF18 protein to the maintenance of apico-basal polarity of retinal cells.
Recently, global proteomics revealed that ARHGEF18 is present in human eosinophils. 13 The eosinophil is a blood granulocyte that is specified during hematopoietic differentiation. 14 The eosinophil has a unique repertoire of granular proteins and cell surface receptors and is prominent in inflammation driven by mediators of T helper cell type 2 immunity. 15 Eosinophils undergo rapid and profound morphological change following cytokine stimulation, 16 going from ovoid to acorn-shaped and polarized in the space of 5 min. The shape change is accompanied by enhanced integrin-mediated adherence to extracellular matrix proteins 17 and is dependent on actomyosin cytoskeleton rearrangement. 16 The ARHGEF18-RHOA-ROCK2-MLC signaling axis regulates actomyosin contractility in other cell types. 9, 11 Roles of ARHGEF18 have not been studied in hematopoietic cells, and if and how ARHGEF18 contributes to mechanisms underlying the dramatic polarization of integrins and receptors to the nucleopod tip in eosinophils is not known.
We now describe previously uncharacterized isoforms of ARHGEF18 in eosinophils. The investigations arose out of recent isobaric labeling mass spectrometric study indicating, unexpectedly and inexplicably, that the abundance of a peptide from LOC100996504, annotated in UniProtKB 18 as a transmembrane protein, decreases acutely upon activation of eosinophils with IL-5. 13 A BLAST search 19 revealed multiple predicted ARHGEF18 isoforms containing part of LOC100996504 based on expressed sequences tags (ESTs). 20 We dub these isoforms the "LOCGEFs. 
MATERIALS AND METHODS

Ethics statement
Peripheral human blood eosinophils were purified to >98% purity by Percoll centrifugation and negative selection for neutrophils and monocytes as described previously. 21 The cells were received without identifying information in accord with a protocol approved (#2013- 
RNA-Seq mapping
We visualized RNA-Seq reads from the Illumina BodyMap 2.0 project 22 (NCBI GEO accession: GSE30611) mapped to human genome build hg19 using Integrative Genome Viewer (IGV). 23 From these data, percentage spliced in (PSI) values were calculated; enabling us to determine predicted proportions of X3, X4, and X5 transcripts.
Raw RNA-Seq datasets generated for neutrophils 24 (GSE40548) and Jurkat T lymphocytes 25 (GSE45428) were processed in the computational biology workflow platform Galaxy, 26 and mapped to human genome build hg19 using the TopHat read alignment algorithm. 27 29 to the genome using the online computational biology platform Galaxy. 26 The mapped reads were visualized using Integrated Genome Viewer, 23 enabling determination of mouse LOCGEF isoforms. These isoforms were then verified through a process of specific amplification and sequencing (see below).
Pairwise sequence alignment
PCR and sequencing of eosinophils' ARHGEF18 isoform transcripts
Preparation of human and mouse eosinophil cDNAs
Human RNA was extracted from peripheral blood eosinophils from donors using the RNeasy kit (Qiagen #74104). Mouse RNA was extracted from cultured bone marrow cells. 30 As previously described, 31 cDNA was generated using the SuperScript R III 
PCR to investigate transcript composition
We created primer pairs (Item Ia of Supplementary Data) specific for some of the ARHGEF18 isoforms (Table 1 ) and used conventional PCR cycling to amplify target regions from eosinophil cDNA, that is, the 5 ′ end of the transcripts that harbor the major differences in human isoform sequences. Transcripts with premature truncations due to alternative splicing (found in X4 and X11) were not evaluated. Although RNA-Seq data suggested that only t1, X3, X4, and X5 are present in white blood cells (see below), the primer pairs created would also recognize t2, X2, and X6. Amplicons were sequenced. We created primer pairs specific for the "LOC" region of the predicted mouse orthologue of LOCGEF (Item Ib of Supplementary Data), and sequenced amplicons to verify our model.
Expression of recombinant p114 and LOCGEF
Amplification of the LOCGEF transcript for cloning
The LOCGEF transcript is 4 kb, and the 3 ′ half is GC-rich (68%).
After failing with several strategies, we succeeded in assembling fulllength cDNA by amplifying and joining 4 overlapping segments making use of internal restriction sites DraI, Bsu36I, and BamHI (Item Ic of Supplementary Data, Supplementary Fig. 1 ). The LOCGEF transcript was cloned with a His-tag sequence at the N-terminus into pET-Elmer (a variant of pET-28c) 32 and amplified in E. coli strain DH5 . The cloned product contained alleles of two single-nucleotide non-synonymous polymorphisms, designated as rs536249774 and rs2287918 in dbSNP. 33 Our cDNA encodes Y211 (exon L8, frequency < 0.01; major allele would encode C) and R889 (exon 22 of fulllength LOCGEF/exon 13 of p114, frequency of 0.83; minor allele with a frequency of 0.17 would encode Q). 33
Amplification of p114, and protein expression and purification of LOCGEF and p114
After the LOCGEF construct was complete, the plasmid was used as template for amplifying the p114 sequence for cloning into pET-Elmer.
Expression of both proteins was induced by IPTG in E. coli BL21 (DE3).
After lysing the bacteria in urea buffer (8 M urea, 100 mM NaH 2 PO 4 , 10 mM Tris, 1 mM -mercaptoethanol pH 8.0), the protein was purified on a Nickel-NTA column. Eluted protein was dialyzed into acetate buffer (100 mM, pH 2.88). Yields were low, but sufficient for use of the proteins as standards in immunoblotting.
Detection of LOCGEF protein in eosinophils 2.5.1 Preparation of cells
Human peripheral blood eosinophils were allowed to rest for 1 h in RPMI with 50 mM HEPES and 0.1% HSA at 37 • C, before being stimulated for 5 min with 50 ng/ml IL-5, 100 ng/ml IL-33, or 30 ng/ml CCL11.
Lysates of eosinophils were prepared using SDS buffer (62.5 mM Tris, 4% SDS, 5% glycerol, 4 M urea pH 6.8) with 700 mMmercaptoethanol. Samples were boiled in 25 l buffer per million cells for 5 min.
Immunoblotting
Antibodies are listed in Item II of Supplementary Data. Samples loaded on gels were prepared from roughly 1 million cells. We used 8% acrylamide gels to resolve lysates, before transferring protein overnight to polyvinylidene fluoride (PVDF) membrane. Membranes were blocked in 1% BSA, before being incubated in polyclonal rabbit or goat anti-ARHGEF18 antibody at 1 g/ml in 0.1% BSA in TBS-T, followed by incubation in 1:10,000 donkey anti-rabbit or bovine anti-goat IgG conjugated to HRP (Jackson ImmunoResearch). Bands were detected by enhanced chemiluminescence and compared to Precision Plus
Protein Kaleidoscope Standard (BioRad). The PVDF membrane was Ponceau stained to evaluate equal loading of lysates. Densitometric analysis was performed using ImageJ. 34 Three representative donors are shown in Results. The experiment was performed several times, with seven biological replicates. 
Immunofluorescent staining
RESULTS
A leukocyte-specific form of ARHGEF18 exists in eosinophils
Discovery and evaluation of LOC100996504 peptides in eosinophils
Our investigation of LOC100996504 was motivated by comparative proteomic studies of resting and IL-5-activated human eosinophils. 13 LOC100996504, which is annotated as an uncharacterized, putative transmembrane protein of 382 residues in UniProtKB, 18 decreased nearly 3-fold in abundance over a 5 min interval of IL-5 stimulation. A comparison of this sequence to database sequences using BLAST, 19 however, revealed that the N-terminal 322 residues of LOC100996504 corresponded to the initial 322 residues encoded by nX5 or nX6 transcripts of ARHGEF18 predicted by NCBI's Eukaryotic Annotation Pipeline's Gnomon-prediction models 20 (Table 1 ). The eosinophil-derived peptides discovered by mass spectrometry 13 were common to both LOC100996504 as annotated in UniProtKB and putative 1361− or 1345−residue X3, X4, and X5 isoforms of ARHGEF18 encoded by the nX5, nX7, and nX8 transcripts (Table 1) . These findings, therefore, focused our attention on ARHGEF18.
Genomic analysis
The DNA sequence encoding the exons of LOC100996504 mapped to a region upstream of the gene annotated as ARHGEF18 on human chromosome 19 ( Fig. 1A and B) . The putative LOC100996504 gene is divided into 10 exons, which herein we number L1-L10 to distinguish them from the 20 exons that comprise the canonical ARHGEF18 t1 for which the initiating methionine codon is in exon 2. The region between the splice site of exon L10 of LOC100996504, and exon 2 of ARHGEF18 is roughly 50 kB and contains noncoding exon 1 of ARHGEF18. Examination of the ENCODE database 35 for RNA polymerase ChIP-Seq hits in this region supported binding site motifs for three transcription factors, including PU.1, localizing near exon L1 and a different set of 5 transcription factors localizing near exon 1 ( Fig. 1A and B) . No highranking transcription factor-binding sites were predicted close to the presumptive transcriptional start site of Isoform 1 (Fig. 1 arrowhead) , a predicted isoform that is discussed further below.
ARHGEF18 transcripts and predicted proteins
We assessed transcript evidence for NCBI-predicted ARHGEF18 isoforms by examination of publicly-available RNA-Seq data from Illumina's BodyMap 2.0 dataset 22 (Fig. 1C) . Mapped reads showed that the transcript for the canonical 114 kDa form of ARHGEF18 (p114) was present in all 16 BodyMap tissue RNA-Seq datasets. In contrast, we found no transcript evidence supporting UniProtKB's 382-residue form of LOC100996504 in any of them, nor was there evidence supporting transcripts t2 (ARHGEF18 in ProteomicsDB, Isoform 1 in UniProtKB), nX6, nX9, nX10, or nX11 (Table 1) . Instead, the mapped read data from white blood cells (WBC) supported three of NCBI's predicted transcript models for ARHGEF18 in which exons L1-L10 of LOC100996504 are spliced to exon 2 of ARHGEF18. These vary in the 5 ′ splice juncture in exon L2 (Fig. 1D ) and are designated nX5, nX7, and nX8; encoding predicted protein isoforms X3, X4, and X5 with differing N-terminal sequences (Table 1 and Fig. 1E ).
We call these proteins "LOCGEFs." The first 322 residues at the Nterminus of LOCGEF-X3 correspond to the N-terminal residues of UniProtKB's LOC100996504 (Fig. 1E) . Analysis of the BodyMap data for PSI values 36 indicated that LOCGEF transcripts in white blood cells comprise mostly nX5 with lesser amounts of nX7 and nX8 (Fig. 1D) .
Analyses of published RNA-Seq reads from neutrophils 24 and Jurkat T cells 25 revealed that >90% of reads spanned the "exL10-ex2" junction compared to the "ex1-ex2" junction of the p114 transcript (data not shown). All of the neutrophil spanning reads supported the nX5 model, whereas of the Jurkat RNA-Seq reads, 91% fit the nX5 model and 9% the nX8 model.
Of the ARHGEF18 transcript models lacking premature stop codons, t1/nX9/nX10, nX5, nX6, and nX8 conform to the most-favored Kozak consensus sequence for translation initiation-gcc(A/G)ccATGg 37 ( Table 1) . None of the RNA-Seq data, however, conformed to the nX6 model, which would encode the same protein as X3 but contains nucleotides from an extra exon between exons L1 and L2.
Thus, the most abundant protein isoforms are likely to be generated from t1, nX5, and nX8 transcripts to yield, respectively, p114, X3, and X5. LOCGEF-nX7 encoding X4 has a less favorable Kozak sequence. Because of the confusing nomenclature for the transcript and isoform models, we suggest that the possible ARHGEF18 isoforms be called canonical p114 and LOCGEF-X3, LOCGEF-X4, and LOCGEF-X5 (Table 1) . 
Proteomic support for LOCGEF isoforms in eosinophils and other leukocytes
Our global proteomic analysis of eosinophils 13 Fig. 2 , Item III in Supplementary Data). Of the discovered unique peptide sequences, 65 are common to both Isoform 1 and 2. As in our analysis, publicly-available proteomic data curated by ProteomicsDB 38 describe LOC100996504 peptides in B-and T-lymphocytes, monocytes, and NK cells, whereas peptides from the p114 form of ARHGEF18 are found in 27 other samples as well as in these (Table 2 ). Neither our nor ProteomicsDB's datasets include peptides corresponding to the final 60 residues of UniProtKB's LOC100996504 sequence, compared to the 83% coverage of the first 322 residues recorded by ProteomicsDB.
In the ProteomicsDB datasets, the ratios of abundances of LOC100996504 relative to ARHGEF18 in sources containing peptides for both ranged from 3 to 14.5 (Table 2) . Intensity-based estimates for these two entries in eosinophils varied by <30%, comparable to the minimal variation in intensities of the subunits of fibrinogen or hemoglobin, 13 contaminating proteins for which subunit stoichiometry is 1:1:1 or 1:1. These data suggest that p114 and LOCGEF isoforms are both present in lymphocytes and monocytes, but exclusively LOCGEF isoforms are found in eosinophils.
Of the peptide sequence matches (PSMs) found in our proteomic analyses, two are common to Isoform 1 and the LOCGEFs but not to p114 ( Supplementary Fig. 3 ). The ProteomicsDB datasets also contain one PSM that is specific for Isoform 1 but not LOCGEF (Supplementary Fig. 3) ; this PSM was identified in studies of A375 39 and U2OS 40 cells. We note that while absence of proof is not proof of absence, the RNA-Seq data lack transcripts matching the full sequence of Isoform 1 as well as that of LOC100996504, and there are no proteomic data to support these models in eosinophils. We propose that PSMs attributed to LOC100996504 derive from LOCGEF and 2 of the 3 peptides considered specific for ARHGEF18 Isoform 1 derive from LOCGEF. We doubt that Isoform 1 exists. However, assessing the PSM mapping only to Isoform 1 would require a targeted proteomics approach.
In all 3 plausible models of LOCGEF, the ARHGEF18 isoform transcript comprises 29 exons in which exon L10 of LOC100996504 is spliced to exon 2 of ARHGEF18, that is, in LOCGEF-X3 966 coding nucleotides extending from exon L1 to a truncated exon L10 (a sequence encoding the initial 322 residues of LOC100996504) are spliced to the 3117 nucleotides of the ARHGEF18 transcript (a sequence encoding 1039 residues) resulting in a protein of 1361 residues ( Table 1 ). The 3 models predict different initiating methionines due to differential splicing of exon L2 (Fig. 1E) . PSMs matching the peptide starting with the initiating methionine predicted for LOC100996504 (and by extension LOCGEF-X3), although not present in our dataset, 13 were found in global proteomic analyses of leukemic 41 and Jurkat T cells. 25 However, because LOCGEF-X4 and LOCGEF-X5 were not annotated in the databases used for these analyses, one cannot conclude that the other N-terminal sequences were not present.
Interrogation of LOCGEF transcripts and proteins in eosinophils
We designed sets of primers spanning predicted exon-exon junctions (Item Ia in Supplementary Data) and sequenced PCR products amplified from human peripheral blood eosinophil cDNA. Importantly, we found that the predicted exonL10-exon2 junction of LOCGEFs was present ( Fig. 2A) . Primers specific for transcripts encoding p114 or Isoform 1 did not yield product when used to amplify eosinophil cDNA.
Primers able to amplify transcripts nX5, nX6, nX7, or nX8 resulted in a dominant nX5 product encoding LOCGEF-X3 (Fig. 2B, lane 3) . In addition, PCR products encoding X4 or X5 were produced using primers that would amplify nX7 or nX8 but not nX5 (Fig. 2B, lane 2) . Sequencing indicated that both sequences were present with the nX8 sequence dominating (Fig. 2C) . We saw no evidence of nX6. Thus, these data show that ARHGEF18 transcripts nX5, nX7, and nX8 (encoding protein isoforms X3, X4, and X5 respectively) are present in eosinophils with an order of abundance of nX5 >> nX8 > nX7 (Fig. 2B and C) , which is in agreement with the proportion of reads mapping across splice junctions in the WBC dataset (Fig. 1D) .
To produce standards for immunoblotting of ARHGEF18 isoforms in eosinophils using commercial anti-human p114 antibodies, we cloned full-length LOCGEF-X3 from eosinophil cDNA ( Supplementary   Fig. 1 ), used the LOCGEF amplicon to generate an amplicon encoding p114, and expressed both proteins in E. coli. Polyclonal antibodies targeting epitopes within the regions of residues 612-802 (rabbit) or the C-terminus 1002-1015 (goat) of p114, which correspond to residues 958-1148 or 1348-1361 of LOCGEF-X3, recognized a protein of roughly 185 kDa in eosinophil lysate ( Fig. 3A and B) . This band is larger than the molecular weight of 152 kDa calculated for LOCGEF-X3 by the ExPASy Compute Mw/pI tool, 42 (Fig. 3C) . Protein content of the PVDF membrane was visualized using Ponceau stain to demonstrate parity of total protein loaded (Fig. 3D) . Densitometric assessment attested to the near equivalence of paired lysates. The ratios shown indicate the IL-5/PBS LOCGEF level, adjusted according to total protein loaded. These data are representative of 7 biological replicates.
One of the sample sets contained a minor immuno-reactive band of 165 kDa. This band was not found in any of the other samples. Since -X4 and -X5 have predicted molecular weights within 2 kDa of that of LOCGEF-X3, it is unlikely that the 165 kDa band represents an intact LOCGEF isoform.
3.1.6
Microscopic localization of LOCGEF in unactivated and activated eosinophils As described in the Introduction, p114 ARHGEF18 is important for establishing neuro-epithelial apico-basal cell polarity. Eosinophils are known to undergo rapid shape change and become polarized upon activation with a number of agonists, including IL-5, CCL11 (eotaxin-1), and IL-33. 16, 43, 44 To explore a possible role of LOCGEF in polarization, we localized goat anti-ARHGEF18 by confocal microscopy in unactivated blood eosinophils or eosinophils activated by 1 of these 3 agonists. Activation was carried out on suspended cells for 10 min, after which cells were fixed and collected by cytospinning prior to staining. LOCGEFs had a discontinuous distribution in the perimembrane region of unactivated cells (Fig. 4A) . Polarization with IL-5 or CCL11 entails movement of the nucleus to one end of the cell to form a structure called the nucleopod because the overlying plasma have transcripts encoding LOCGEF-X3, -X4, and -X5. (A) Sequencing of LOCGEF amplicons demonstrating splicing of exon L10 exon 2 in eosinophil cDNA. (B) PCR of eosinophil cDNA demonstrating presence of nX5 and nX7/nX8 transcripts in eosinophils. Lane 1, exACTGene DNA ladder; lane 2, nX7/nX8 amplicons; lane 3, nX5/6/7/8 amplicons. The band in lane 2 is of the expected size for primers that amplify nX7, 358 bp; or nX8, 362 bp. The major band in lane 3 is of the expected amplicon size for nX5, 248 bp; and the minor band is of the expected amplicon size for nX7, 297 bp; or nX8, 301 bp. No band of the size expected for nX6, 411 bp, was found. (C) Sequencing of the nX7/nX8 amplicons demonstrating presence of both nX7 and nX8, which cannot be distinguished by gel electrophoresis membrane is enriched in proteins that are markers of uropods in other leukocytes. 16 Upon activation with IL-5, IL-5 receptors become clustered at the tip of the nucleus, and activated JAK2, STAT1, and STAT5 are found in proximity to this cluster. 16 STAT3 is also part of the JAK-STAT signaling pathway and has heretofore not been localized in human eosinophils. 45 After activation with IL-5, LOCGEF was concentrated in the nucleopod tip, partially overlapping with STAT3 that was similarly concentrated in the nucleopod (Fig. 4B) . LOCGEF, but not STAT3, also was enriched in apparent membrane protrusions at the opposite pole of the cell. Treatment with IL-33 or CCL11 resulted in less dramatic polarization, that is, movement of the nucleus into to one side of the cell without formation of a distinct nucleopod tip. LOCGEF was enriched in the half of the cells containing the nucleus and in the membrane protrusions at the opposite end ( Fig. 4C and D) . To assess the significance of relocalization during activation, LOCGEF was costained with RHOA or RAC2, the major Rho and Rac family members in eosinophils. 13 RHOA had a peri-membranous distribution in unactivated eosinophils and became enriched along with LOCGEF (arrow) in the nucleopod and in protrusions at the opposite pole (arrowhead).
In contrast, RAC2, as described previously in guinea pig eosinophils, 46 localized to granules and moved with the granules to one side on the cell upon activation. RAC2 did not colocalize with LOCGEF in either unactivated or activated eosinophils.
LOCGEF orthologues
To identify model organisms amenable for genetic study of LOCGEF, 
DISCUSSION
Herein, we demonstrate that the major isoform of ARHGEF18 in human eosinophils is a 1361-residue protein, LOCGEF-X3, comprising the 1015-residues of p114 isoform and an additional 346 N-terminal residues. We further show that there are transcripts for 2 other potential extended ARHGEF18 isoforms, LOCGEF-X5 and LOCGEF-X4, differing at the extreme N-terminus. RNA-Seq and proteomics data indicate that LOCGEF isoforms are unique to leukocytes whereas the p114 isoform is ubiquitous in non-hematopoietic tissues. The p114 isoform was not detected in eosinophils either as transcript or protein.
Expression of the LOCGEF and p114 isoforms is presumably dictated by factors targeting 2 possible transcriptional start sites in exon L1 (for LOCGEF isoforms) and exon 1 (p114). The transcriptional start sites match ChIP-Seq data showing transcription factor clustering.
PU.1 (SPI1), found by ChIP-Seq to bind close to exon L1 along with c-Myc and Max (Fig. 1A) , is an important regulator of hematopoiesis. 48 Eosinophils are specified early in hematopoiesis, 14 and PU.1 is upregulated in eosinophil progenitor cells. 49 PU.1 is also abundant in differentiated peripheral blood eosinophils. 13 In contrast, the transcription factors predicted to bind in the vicinity of exon 1 of the shorter ARHGEF18 isoform (p114) are more widely expressed. 50 Inasmuch as LOCGEFs may participate in various Rho GTPase-regulated events that are important during hematopoiesis (reviewed in 51 ), it will be of interest to study the contribution of LOCGEF function during hematopoietic differentiation as well as in differentiated hematopoietic cells.
The discrepancy between immunoblotting, which demonstrated no differences in abundance of LOCGEF in unstimulated and IL-5-stimulated eosinophils, and mass spectrometry of isobaric labeled peptides, which reported such a difference for LOC10096504, prompted us to review the spectra of the 2 LOC100996504 peptides and 24 other ARHGEF18 peptides that were found in our analysis. 13 a requirement for remodeling of the actin cytoskeleton. 16 The relocalization of LOCGEF to the two poles of eosinophil upon activation suggest a role for LOCGEF in modulation of such cytoskeletally-driven shape change. 16 Eosinophil polarization is important for adherence of circulating eosinophils to inflamed vessels in intravital experiments, 57 and RHOA and RHOA-associated coiled-coil kinase 2 (ROCK2) have previously been shown to have roles in uropod detachment of eosinophils and neutrophils during migration. 58, 59 We propose, therefore, that just as ARHGEF18-RHOA-ROCK2-MLC signaling axis regulates actomyosin contractility in other cell types, 9,11 LOCGEF acts upon RHOA in eosinophils to drive shape change prior to eosinophil adhesion and movement of eosinophils upon adhesion. We note that LOCGEF is not the only RHOA GTPase-regulating guanine nucleotide exchange factor in eosinophils-ARHGEF1 and 2 are both present in equal abundance, 13 and it is likely the LOCGEF cooperates with the others in spatiotemporal regulation of RHOA activity. In contrast, there was no overlap of LOCGEF with RAC2, which is a leukocytespecific guanine nucleotide exchange factor that regulates granular NADPH oxidase and superoxide formation, 46 in the 3 stimulatory conditions. Rather, the distribution of RAC2 is suggestive of a role regulating actin scaffolding in the granulomeric region. 
